HDAC6 and Alzheimer disease: The HDAC6 inhibitor vorinostat is currently in a phase Ib study for patients with AD (ClinicalTrials.gov NCT03056495), and the HDAC6 inhibitor nicotinamide is currently in a phase II trial for AD (NCT03061474).